Skip to content

Correlation between Novel Inflammatory Markers and Pulmonary Artery Systolic Pressure and Prognosis in Patients with Heart Failure Complicated by Pulmonary Hypertension

Correlation between Novel Inflammatory Markers and Pulmonary Artery Systolic Pressure and Prognosis in Patients with Heart Failure Complicated by Pulmonary Hypertension

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120779
Enrollment
Unknown
Registered
2026-03-19
Start date
2025-07-11
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension due to left heart disease

Interventions

Heart Failure with Preserved Ejection Fraction Combined with Pulmonary HypertensionHeart Failure with Reduced Ejection Fraction or Mildly Reduced Ejection Fraction Combined with Pulmonary Hypertension
Heart Failure with Reduced or Mildly Reduced Ejection Fraction and Pulmonary Hypertension:no

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 85 years. 2. Diagnosis of heart failure meeting the criteria outlined in the 2024 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure: (1) Presence of heart failure symptoms and/or signs; (2) Elevated natriuretic peptide levels (BNP >=35 pg/mL or NT-proBNP >=125 pg/mL); (3) Evidence of cardiac structural and/or functional abnormalities. 3. Echocardiography indicates a pulmonary artery systolic pressure (or right ventricular systolic pressure) >=35 mmHg.

Exclusion criteria

Exclusion criteria: 1. PH due to other etiologies, such as pulmonary arterial hypertension, PH due to lung diseases and/or hypoxia, chronic thromboembolic PH, and PH with unclear and/or multifactorial mechanisms. 2. Conditions affecting complete blood count results, including hematological diseases, hyperthyroidism and hypothyroidism, presence of chronic inflammation or acute infection, etc. 3. Moderate or severe valvular stenosis or regurgitation. 4. Severe hepatic or renal dysfunction, malignant tumors, and other non-cardiac diseases limiting life expectancy. 5. Lack of complete blood count data or relevant clinical information. 6. Inability to cooperate with follow-up.

Design outcomes

Primary

MeasureTime frame
High and Low Systemic Inflammatory Response Index ;Pulmonary Artery Systolic Pressure;

Countries

China

Contacts

Public ContactYan Liu

The First Affiliated Hospital of Dalian Medical University

15541191236@163.com+86 180 9887 5820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026